7 completed. 7 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 2 | 1 | Completed 1 |
Follow Acromegaly: new trials by email Literature Review of Acromegaly trials Research Report on Acromegaly
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25) T25-Fast, Mycapssa, T25-Fed - Acromegaly | Phase 1 | Completed | Triastek (Shanghai) Limited | 18 | 2026-06-25 | 2026-09-16 |
| A Phase 1 Study of TE-8214 Solution in Healthy Volunteers TE-8214 - SAD, Placebo - Acromegaly | Phase 1 | Completed | Immunwork, Inc. | 32 | 2024-06-18 | 2025-05-20 |
| A Single-dose Study of Octreotide Injection in Healthy Adult Subjects SYHX2008 injection, Octreotide Acetate Microspheres for Injection injection, Sandostatin ® injection - Acromegaly | Phase 1 | Completed | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 56 | 2023-03-02 | 2023-10-10 |
| Vitamin D Metabolism in Patients With Endocrine Disorders Cholecalciferol 15000 UNT/ML Oral Solution - Pituitary ACTH Hypersecretion, Acromegaly | Phase 1 | Completed | Endocrinology Research Centre, Moscow | 261 | 2019-04-16 | 2022-08-11 |
| Single-dose Study to Evaluate the Absolute Bioavailability and Mass Balance of ONO-5788 ONO-5788, [14C]-ONO-5788 - Acromegaly | Phase 1 | Completed | Ono Pharmaceutical Co., Ltd. | 12 | 2019-02-27 | 2019-11-07 |
| Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly Lanreotide PRF - Acromegaly | Phase 1 / Phase 2 | Completed | Ipsen | 28 | 2015-03-01 | 2019-04-25 |
| Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease Pasireotide - Carcinoid Tumor, Acromegaly | Phase 1 | Completed | Novartis Pharmaceuticals | 85 | 2006-06-01 | 2020-12-21 |
Carcinoid Tumor (1) · Diabetes Mellitus, Type 1 (1) · Hyperparathyroidism, Primary (1) · Pituitary ACTH Hypersecretion (1) · Vitamin D Deficiency (1)
Bone Diseases (7) · Bone Diseases, Endocrine (7) · Brain Diseases (7) · Central Nervous System Diseases (7) · Endocrine System Diseases (7) · Hyperpituitarism (7) · Hypothalamic Diseases (7) · Musculoskeletal Diseases (7) · Nervous System Diseases (7) · Pituitary Diseases (7) · Adenocarcinoma (1) · Autoimmune Diseases (1) · Avitaminosis (1) · Carcinoma (1) · Deficiency Diseases (1)
Octreotide (2) · Injections (1) · lanreotide (1) · pasireotide (1)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Endocrinology Research Centre, Moscow (1) · Immunwork, Inc. (1) · Ipsen (1) · Novartis Pharmaceuticals (1) · Ono Pharmaceutical Co., Ltd. (1) · Triastek (Shanghai) Limited (1)
Netherlands (3) · Belgium (2) · China (2) · Germany (2) · Russia (2) · Australia (1) · Canada (1) · Czechia (1) · France (1) · Italy (1) · Lithuania (1) · Norway (1) · Poland (1) · Romania (1) · Spain (1)
Jan Jaap van Lier, MD (1) · Liudmila Rozhinskaya, MD, PhD (1) · Shan NA Jing, PhD (1) · Yang NA Lin, PhD (1)
PMID 24800725, PMID 34664531, PMID 35138562, PMID 42712757
2005 (1), 2014 (1)